CAMBRIDGE, United Kingdom, Feb. 16, 2026 (GLOBE NEWSWIRE) -- LEX Diagnostics, a leading innovator in molecular diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and ...
– Company Expects to Initiate U.S. Commercial Launch of the LEX VELO System Later This Year – SAN DIEGO, April 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL ) (the "Company" or ...
CAMBRIDGE, England--(BUSINESS WIRE)--TTP today announced the acquisition by QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based ...
CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug ...
LEX Diagnostics, a leading innovator in molecular diagnostics, has received US Food and Drug Administration (FDA) 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast ...
Ultra-fast point-of-care molecular diagnostics platform for key respiratory pathogens delivers results in under ten minutes CAMBRIDGE, United Kingdom, Feb. 16, 2026 (GLOBE NEWSWIRE) -- LEX Diagnostics ...